Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201656 · ClinicalTrials.gov registry record · Phase 4
Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)
A Phase 4 study, sponsored by Obstetrix Medical Group.
- Terminated
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00201656: Clinical Trial Phase 4 study, sponsored by Obstetrix Medical Group.
NCT00201656 is a Phase 4 study that was terminated before completion, run by Obstetrix Medical Group. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00201656, a Phase 4 study, was terminated before completion, sponsored by Obstetrix Medical Group.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether retention of cervical cerclage after PPROM improves latency (without a significant increase in chorioamnionitis) and lessens neonatal morbidity.
Interventions
- PROCEDURE Retention of Cerclage
- PROCEDURE Removal of Cerclage
- PROCEDURE Removal vs. Retention of Cervical Cerclage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2004-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Why NCT00201656 stopped before completion
NCT00201656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Retention of Cerclage is the first listed.
NCT00201656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00201656 about?
NCT00201656 is a clinical study titled "Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)". The purpose of this study is to determine whether retention of cervical cerclage after PPROM improves latency (without a significant increase in chorioamnionitis) and lessens neonatal morbidity.
What is the current status of trial NCT00201656?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2004-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00201656?
The interventions under investigation include: Retention of Cerclage (PROCEDURE), Removal of Cerclage (PROCEDURE), Removal vs. Retention of Cervical Cerclage (PROCEDURE).
Who is sponsoring clinical trial NCT00201656?
This trial is sponsored by Obstetrix Medical Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00201656's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia